Cadogan Cathal A, Murphy Melanie, Boland Miriam, Bennett Kathleen, McLean Sarah, Hughes Carmel
School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Ireland.
School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Ireland.
Explor Res Clin Soc Pharm. 2021 Jul 23;3:100050. doi: 10.1016/j.rcsop.2021.100050. eCollection 2021 Sep.
Patients receiving palliative care often have existing comorbidities necessitating the prescribing of multiple medications. To maximize quality of life in this patient cohort, it is important to tailor prescribing of medication for preventing and treating existing illnesses and those for controlling symptoms, such as pain, according to individual specific needs.
To provide an overview of peer-reviewed observational research on prescribing practices, patterns, and potential harms in patients receiving palliative care.
A systematic scoping review was conducted using four electronic databases (PubMed, EMBASE, CINAHL, Web of Science). Each database was searched from inception to May 2020. Search terms included 'palliative care,' 'end of life,' and 'prescribing.' Eligible studies had to examine prescribing for adults (≥18 years) receiving palliative care in any setting as a study aim or outcome. Studies focusing on single medication types (e.g., opioids), medication classes (e.g., chemotherapy), or clinical indications (e.g., pain) were excluded. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for scoping reviews, and the findings were described using narrative synthesis.
Following deduplication, 16,565 unique citations were reviewed, and 56 studies met inclusion criteria. The average number of prescribed medications per patient ranged from 3 to 23. Typically, prescribing changes involved decreases in preventative medications and increases in symptom-specific medications closer to the time of death. Twenty-one studies assessed the appropriateness of prescribing using various tools. The prevalence of patients with ≥1 potentially inappropriate prescription ranged from 15 to 92%. Three studies reported on adverse drug events.
This scoping review provides a broad overview of existing research and shows that many patients receiving palliative care receive multiple medications closer to the time of death. Future research should focus in greater detail on prescribing appropriateness using tools specifically developed to guide prescribing in palliative care and the potential for harm.
接受姑息治疗的患者通常患有多种合并症,需要开具多种药物。为了使该患者群体的生活质量最大化,根据个体特定需求调整用于预防和治疗现有疾病以及控制症状(如疼痛)的药物处方非常重要。
概述关于接受姑息治疗患者的处方实践、模式和潜在危害的同行评审观察性研究。
使用四个电子数据库(PubMed、EMBASE、CINAHL、Web of Science)进行系统的范围综述。每个数据库从创建到2020年5月进行搜索。搜索词包括“姑息治疗”“生命末期”和“处方”。符合条件的研究必须将在任何环境中接受姑息治疗的成年人(≥18岁)的处方作为研究目的或结果进行检查。专注于单一药物类型(如阿片类药物)、药物类别(如化疗)或临床适应症(如疼痛)的研究被排除。该综述遵循系统评价和Meta分析的首选报告项目(PRISMA)范围综述指南,并使用叙述性综合描述研究结果。
在去重后,共审查了16565条独特的引文,56项研究符合纳入标准。每位患者的平均处方药物数量在3至23种之间。通常,处方变化包括在接近死亡时预防性药物减少,症状特异性药物增加。21项研究使用各种工具评估了处方的适当性。有≥1种潜在不适当处方的患者患病率在15%至92%之间。三项研究报告了药物不良事件。
这项范围综述提供了现有研究的广泛概述,并表明许多接受姑息治疗的患者在接近死亡时接受多种药物治疗。未来的研究应更详细地关注使用专门为指导姑息治疗处方而开发的工具的处方适当性以及潜在危害。